After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari (sparsentan) to full approval…
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari (sparsentan) to full approval…
Investors are rallying around the promise of cross-species transplantation, enabling eGenesis to close a $191m Series D financing round to…
It looks like Lexicon Pharmaceuticals’ second bid to get US Food and Drug Administration (FDA) approval for Zynquista (sotagliflozin) will…
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
AstraZeneca has highlighted both the economic and environmental benefits of implementing early, targeted screening for chronic kidney disease (CKD). CKD…
Travere Therapeutics has signed a licensing agreement for sparsentan with Japan-based Renalys Pharma for multiple Asian countries. As per the…
Novartis plans to discuss the filing of its drug iptacopan in C3 glomerulopathy with global health authorities on the back…
Ipspen and Genfit’s elafibranor has received priority review designation from the US Food and Drug Administration (FDA) for the treatment…
Travere Therapeutics has implemented a 20% reduction of its workforce to funnel resources into Filspari’s (sparsentan) launch in IgA nephropathy…
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Ardelyx’s Xphozah (tenapanor) for the treatment…